An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism

Current Opinion in Neurology

Volumn 18, Issue 4, 2005, Pages 370-375

  Seppi, Klaus ^a   Schocke, Michael F H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Atypical parkinsonian disorders; Diffusion weighted imaging; Magnetic resonance spectroscopy; Magnetization transfer imaging; MR volumetry; MRI; Parkinson's disease

Indexed keywords

BRAIN TUMOR; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; HUMAN; INTERMETHOD COMPARISON; MORPHOMETRICS; MULTIPLE SCLEROSIS; NORMOTENSIVE HYDROCEPHALUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONISM; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOLUMETRY;

EID: 23344435135     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000173141.74137.63     Document Type: Review

References (79)

1. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18:467-486.
2. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125:861-870.
3. Muller J, Wenning GK, Jellinger K, et al. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000; 55:888-891.
4. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117:1183-1196.
5. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60:615-620.
6. Wenning GK, Ben Shlomo Y, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117:835-845.
7. Seppi K, Yekhlef F, Diem A, et al. Progression of parkinsonism in multiple system atrophy. J Neurol 2005; 252:91-96.
8. Redmond DE Jr, Leranth C, Spencer DD, et al. Fetal neural graft survival. Lancet 1990; 336:820-822.
9. Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327:1541-1548.
10. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998; 339:1130-1143.
11. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339:1044-1053.
12. Drayer BP, Olanow W, Burger P, et al. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986; 159:493-498.
13. Pastakia B, Polinsky R, Di Chiro G, et al. Multiple system atrophy (Shy-Drager syndrome): MR imaging. Radiology 1986; 159:499-502.
14. Tranchant C, Bhatia KP, Marsden CD. Movement disorders in multiple sclerosis. Mov Disord 1995; 10:418-423.
15. Sibon I, Tison F. Vascular parkinsonism. Curr Opin Neurol 2004; 17:49-54.
16. Krauss JK, Paduch T, Mundinger F, Seeger W. Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia. Acta Neurochir (Wien) 1995; 133:22-29.
17. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 2004; 11:5-12.
18. Saatci I, Topcu M, Baltaoglu FF, et al. Cranial MR findings in Wilson's disease. Acta Radiol 1997; 38:250-258.
19. Manyam BV, Bhatt MH, Moore WD, et al. Bilateral striopallidodentate calcinosis: cerebrospinal fluid, imaging, and electrophysiological studies. Ann Neurol 1992; 31:379-384.
20. Rutledge JN, Hilal SK, Silver AJ, et al. Study of movement disorders and brain iron by MR. AJR Am J Roentgenol 1987; 149:365-379.
21. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000; 247(Suppl 2): II11-II18.
22. Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003; 24(Suppl 1):S35-S37.
23. Hutchinson M, Raff U. Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra. J Neurol Neurosurg Psychiatry 1999; 67:815-818.
24. Hu MT, White SJ, Herlihy AH, et al. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 2001; 56:1195-1200.
25. Savoiardo M, Girotti F, Strada L, Ciceri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl 1994; 42:93-110.
26. Hutchinson M, Raff U, Lebedev S. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM). Neuroimage 2003; 20:1899-1902.
27. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998; 65:65-71.
28. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54:697-702.
29. Schulz JB, Klockgether T, Petersen D, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57:1047-1056.
30. Bhattacharya K, Saadia D, Eisenkraft B, et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002; 59:835-842.
31. Kraft E, Schwarz J, Trenkwalder C, et al. The combination of hypointense and hyperintense signal changes on T2- weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999; 56:225-228.
32. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002; 58:575-580.
33. Lee EA, Cho HI, Kim SS, Lee WY. Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. Parkinsonism Relat Disord 2004; 10:363-368.
34. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients. Brain 2002; 125:1070-1083.
35. Horimoto Y, Aiba I, Yasuda T, et al. Longitudinal MRI study of multiple system atrophy - when do the findings appear, and what is the course? J Neurol 2002; 249:847-854.
36. Righini A, Antonini A, Ferrarini M, et al. Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. J Comput Assist Tomogr 2002; 26:266-271.
37. Kraft E, Trenkwalder C, Auer DP. T2'-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology 2002; 59:1265-1267.
38. Soliveri P, Monza D, Paridi D, et al. Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 1999; 53:502-507.
39. Paviour DC, Price SL, Stevens JM, et al. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005; 64:675-679.
40. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001; 58:1076-1079.
41. Righini A, Antonini A, de Notaris R, et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol 2004; 25:927-932.
42. Hauser RA, Murtaugh FR, Akhter K, et al. Magnetic resonance imaging of corticobasal degeneration. J Neuroimaging 1996; 6:222-226.
43. Winkelmann J, Auer DP, Lechner C, et al. Magnetic resonance imaging findings in corticobasal degeneration. Mov Disord 1999; 14:669-673.
44. Josephs KA, Tang-Wai DF, Edland SD, et al. Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol 2004; 61:1881-1884. This paper shows similar patterns of regional atrophy as well as white-matter signal changes on cMRI in patients with post-mortem-confirmed corticobasal syndrome due to corticobasal degeneration and other neurodegenerative conditions.
45. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999; 45:65-74.
46. Ghaemi M, Hilker R, Rudolf J, et al. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73:517-523.
47. Cordato NJ, Pantelis C, Halliday GM, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002; 125:789-800.
48. Groschel K, Hauser TK, Luft A, et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004; 21:714-724.
49. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000; 11:805-821.
50. Burton EJ, McKeith IG, Burn DJ, et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127:791-800.
51. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005; 64:224-229.
52. Summerfield C, Junque C, Tolosa E, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005; 62:281-285.
53. Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003; 18:1132-1138.
54. Specht K, Minnerop M, Muller-Hubenthal J, Klockgether T. Voxel-based analysis of multiple-system atrophy of cerebellar type: complementary results by combining voxel-based morphometry and voxel-based relaxometry. Neuroimage 2005; 25:287-293. This article suggests that the combination of VBM and VBR provides convergent and complementary information about the brain morphology in neurodegenerative diseases such as MSA.
55. Specht K, Minnerop M, Abele M, et al. In vivo voxel-based morphometry in multiple system atrophy of the cerebellar type. Arch Neurol 2003; 60:1431-1435.
56. Brenneis C, Seppi K, Schocke M, et al. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004; 75:246-249.
57. Price S, Paviour D, Scahill R, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage 2004; 23:663-669. This article discusses the clinical utility of VBM results for the differential diagnosis of PSP from Parkinson's disease and controls.
58. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 1989; 10:135-144.
59. Van Buchem MA, McGowan JC, Grossman RI. Magnetization transfer histogram methodology: its clinical and neuropsychological correlates. Neurology 1999; 53:S23-S28.
60. Hanyu H, Asano T, Sakurai H, et al. Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and in progressive supranuclear palsy. Neuroradiology 2001; 43:542-546.
61. Naka H, Imon Y, Ohshita T, et al. Magnetization transfer measurements of brain structures in patients with multiple system atrophy. Neuroimage 2002; 17:1572-1578.
62. Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004; 21:229-235. This is the first article describing the application of MTI for the differential diagnosis of neurodegenerative parkinsonism.
63. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 2003; 4:469-480.
64. Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage 2004; 21:1443-1451. This article shows that abnormal diffusivity in the putamen of patients with MSA-P correlates with disease severity, indicating eventually the capability of putaminal diffusivity to serve as a marker for disease progression.
65. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry 2004; 75:481-484. In this important article on seven early Parkinson's disease patients, the authors suggest that close comparison of fractional anisotropy in the basal ganglia may contribute to the early diagnosis of Parkinson's disease.
66. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60:922-927.
67. 123I] iodobenzamide SPECT.
68. Kanazawa M, Shimohata T, Terajima K, et al. Quantitative evaluation of brainstem involvement in multiple system atrophy by diffusion-weighted MR imaging. J Neurol 2004; 251:1121-1124.
69. Schwarz J, Tatsch K, Gasser T, et al. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13:16-19.
70. Schwarz J, Tatsch K, Gasser T, et al. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord 1997; 12:898-902.
71. Brucke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11:220-228.
72. Trabesinger AH, Meier D, Boesiger P. In vivo 1H NMR spectroscopy of individual human brain metabolites at moderate field strengths. Magn Reson Imaging 2003; 21:1295-1302.
73. Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 2002; 14:64-76.
74. Schocke MF, Berger T, Felber SR, et al. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. Neuroimage 2003; 20:1253-1263.
75. Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995; 37:204-210.
76. Federico F, Simone IL, Lucivero V, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov Disord 1997; 12:903-909.
77. Federico F, Simone IL, Lucivero V, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62:239-242.
78. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 2001; 8:573-577.
79. 1H-MRS at 3.0 T, in which the authors suggest that combined assessment of N-acetylaspartate/creatine in the pontine basis and putamen may be effective in differentiating MSA-P from Parkinson's disease.